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Amyotrophic lateral sclerosis is a devastating neurodegenerative disease affecting both upper and lower motor neuron. Despite 
extensive research the primary cause of the disease has not been indentified and the causative treatment is lacking. The present 
article describes mechanisms involved in the disease development and progression, including oxidative stress, excitotoxicity, 
mitochondrial dysfunction, protein aggregation, RNA processing, alterations of cytoskeleton functions and axonal transport, 
glial cell involvement and programmed cell death. Biomed Rev 2011; 22: 7-14.
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INTROduCTION
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative 
disease affecting up to 500 000 people worldwide. It is caused 
by a selective and progressive loss of upper motor neurons 
of the corticospinal and corticobulbar tracts and lower motor 
neurons localized in the brain stem and anterior horns of the 
spinal cord. At present ALS is an incurable disease leading to 
respiratory insufficiency and death within three years from 
onset. The symptoms usually start in the fifth decade but they 
may become apparent before the age of thirty or over the age 
of 70. The onset is either bulbar or spinal. In the bulbar form, 
the main symptoms include dysarthria and dysphagia. The limb 
symptoms start with asymmetric muscle paresis and wasting 
either in distal or, less frequently, in proximal muscles. Both 
forms end up involving all voluntary muscles with the excep-
tion of sphincters. There is no sensory involvement. The dis-
ease progression varies between individuals. In approximately 
20% of patients the survival exceeds 5 years and only in about 
10%, more than 10 years (1). There is no causative treatment. A 
vast majority of ALS cases are sporadic (sporadic ALS, SALS). 
Only approximately 10% of cases are inherited, mainly as an 
autosomal dominant trait (familial ALS, FALS). Up to 23% 
of FALS and 7% of SALS cases are due to mutations in the 
SOD1 gene (2). Eight percent of FALS and over 1% of SALS 
cases are caused by mutations in TARDBP and FUS/TLS, two 
recently discovered genes encoding for proteins involved in 
RNA processing (3). Other genetic factors among which the 
proteins alsin, progranulin, angiogenin, vascular endothelial 
cell growth factor, vesicle-associated membrane protein and 
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senataxin are less frequent. 
The present article highlights recent advances in our un-
derstanding of molecular mechanisms responsible for ALS. 
OxIdATIvE STRESS
Radical oxygen species (ROS) are reactive forms of oxygen 
containing one unpaired electron. They can easily peroxidize 
organic and inorganic compounds changing their structural 
and functional properties. Lipid peroxidation may influence 
cell membrane permeability. Oxidation of proteins leads to 
alteration of their enzymatic activity and/or conformation. 
When reacting with nucleic acids, ROS may lead to mutagen-
esis. Radical oxygen species are synthesized in reactions of 
respiratory chain or beta-oxidation. In physiological conditions 
they are efficiently neutralized by a number of enzymatic and 
non-enzymatic cell defense mechanisms. However, the imbal-
ance between their production and removal leads to oxidative 
stress. CuZn superoxide dismutase (SOD1) is a free radical 
scavenging enzyme, catalyzing the reaction of peroxidation 
of oxygen peroxide (O2•-) to hydrogen peroxide (H2O2) and 
oxygen: O2 •-+ O2 •- + H2 → H2O2 + O2.The discovery of mu-
tation in the SOD1 gene in FALS in 1993 directed the studies 
on ALS pathogenesis toward the role of oxidative stress (4). 
It was primarily suggested that mutations in SOD1 de-
creased cell capability of neutralizing ROS. However, in many 
cases of SOD1 mutations there were no changes in SOD1 
enzymatic activity. Transgenic mice harboring FALS-linked 
SOD1 mutations demonstrate normal or enhanced enzymatic 
activity (5). Moreover, it was proved that transgenic mice 
either knocked-out for SOD1 or over-expressing the wild 
type SOD1 (wtSOD1) did not develop motor neuron disease 
(MND) (6). Interestingly enough, transgenic mice harboring 
human mutated SOD1 develop MND despite normal expres-
sion of wtSOD1 (7). It was therefore postulated that mutations 
in SOD1 gene induce a toxic gain of function of the encoded 
protein (8). Hundred fifty seven ALS-linked mutations in the 
SOD1 have been reported to date (for complete list please refer 
to http://www.alsod.org, http:// alsod1.iop.kcl.ac.uk/reports/
mutations). Currently proposed mechanism of mutated SOD1-
induced neurodegeneration include alteration of substrate 
specificity and instability of mutated protein (9). Nevertheless, 
nearly 20 years after the discovery, the exact mechanism in 
which the mutations lead to selective death of motor neurons 
remains unknown. 
Despite the lack of influence of decreased SOD1 activity on 
the clinical course of ALS, several studies have shown signs of 
alteration of ROS scavenging mechanisms in MND (reviewed 
in 10). Increased concentration of carbonyl groups (products 
of protein peroxidation), malone dialdehyde (products of lipids 
peroxidation), and 8-OHdG (nucleic acids) was found in cortex 
and/or spinal cord of patients who died in course of SALS 
(10,11). There was an increase of 3-nitrotyrozine (products of 
tyrosine peroxidation) concentration in anterior horns of the 
spinal cord in both SALS and FALS patients. High level of 
8-OHdG and hydroxynonenal (lipid peroxidation product) was 
observed in CSF of patients suffering from ALS. The presence 
of peroxidation products of proteins, lipids and nucleic acids 
was also shown in mouse transgenic models of MND both 
at pre symptomatic and symptomatic stage (10). Antioxidant 
treatment was able to delay disease onset and progression in 
SOD1-transgenic mice, but all completed clinical trials in 
ALS patients showed no clinical efficacy of antioxidants (1).
ExCITOTOxICITY
A report on increased glutamate concentration in CSF of ALS 
patients directed the pathogenetic studies toward excitatory 
amino acids (12). Exposition of cultured motor neurons to 
glutamate or aspartate was shown to induce cell death by ap-
optosis or necrosis, dependent on the amino acid concentration 
(13,14). In physiological conditions, activation of glutaminer-
gic receptors, mainly N-methyl-D-aspartate (NMDA) recep-
tors, leads to opening of post-synaptic calcium channels and 
the intracellular influx of Ca+2. Given the role of calcium ions 
in regulation of cellular growth, differentiation and synaptic 
activity, maintaining the calcium homeostasis is vital. For this 
reason, an excessive activation of glutaminergic receptors due 
to pathologically increased glutamate concentration may alter 
calcium homeostasis and lead to cell death. The main protein 
responsible for a reduction of glutamate concentration in the 
synaptic cleft is a glial transporter of excitatory amino acids 
(EAAT2). It is a Na+-dependent protein localized on the surface 
of glial cells, involved in presynaptic uptake of the glutamate. 
EAAT2 is particularly vulnerable to oxidative stress (15). 
Excessive influx of calcium ions due to activation of glutamin-
ergic receptors leads to increased mitochondrial production of 
ROS, which alter EAAT2 function and increase excitotoxicity. 
Defects in EAAT2 have been found in 80% of SALS patients 
(16). Decrease of EAAT2 concentration was observed in brains 
of patients who died in course of ALS. In transgenic models 
of the disease, reduced EAAT2 expression correlated with 
increased concentration of glutamate in the nervous system 
(17). Riluzole, an inhibitor of NMDA receptors, is at present 
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the only drug for ALS approved by Food and Drug Adminis-
tration in USA and by European Medicines Agency. Although 
its accurate mechanism of action remains unclear, it inhibits 
glutamate release from presynaptic membrane, increases 
its extracellular uptake and stabilizes voltage-gated sodium 
channels in inactive state (18). An 18-month treatment with 
riluzole prolongs patients’ survival by approximately 7% (19).
Until 20 years ago, the NMDA receptor was the only 
glutamate receptor known to be Ca2+-permeable. It is now 
well established that the ionotropic alpha-amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid (AMPA) receptor of 
glutamate is densely distributed in the mammalian brain and 
is involved in mediating fast excitatory synaptic transmission, 
motor neurons showing selective vulnerability to activation 
of AMPA receptors; expression of modified human AMPA 
receptor in transgenic animals induces MND (20). The perme-
ability of AMPA receptors for calcium ions depends on their 
subunit structure (21). Increased expression of GluR3, one of 
the AMPA receptor subunits, in motor neurons carrying SOD1 
mutations increases their susceptibility to kainate-induced ex-
citotoxicity. The toxicity results from facilitation of the Ca2+ 
influx (22). Antisense oligonucleotides therapy against GluR3 
was able to delay motor impairment and extend survival of 
transgenic mice with SOD1 mutation (23). Human trials have 
not been performed.
Noteworthy, recent data suggests a crosstalk between gluta-
mate receptors and brain-derived neurotrophic factor (BDNF) 
in modulating synaptic functions (24,25, also see 20-22). Such 
a BDNF-NMDA/ AMPA receptor signaling might be pursued 
in the pathogenesis and therapy of ALS.
MITOCHONdRIAL dYSFuNCTION
Post mortem studies in ALS revealed the presence of ab-
normal mitochondria localized under the sarcolemma, in 
synaptic terminals and in anterior horn cells (26). Muscle 
biopsies performed in ALS showed big mitochondria with 
increased calcium concentration (26). There were also reports 
on impaired activity of complex I and IV of the respiratory 
chain (encoded by mitochondrial DNA) in skeletal muscles 
and spinal cord of ALS patients (27). In transgenic models 
of ALS with human SOD1 mutation, aggregates of abnormal 
mitochondria with dilated external membrane were found 
within the motor neurons. They resulted from membrane de-
tachment, which occurred after aggregation of mutated SOD1 
in the intermembrane space of mitochondria. The presence of 
these structures early in course of the disease, when the loss of 
motor neurons is not yet accompanied by clinical symptoms, 
points at an active role of mitochondria in ALS pathogenesis 
(28). Currently, there are 2 clinical studies with the use of mi-
tochondrial protection agents, which may show some promise 
in the treatment of ALS. Among them there are tamoxifen, 
which binds to the mitochondrial permeability transition pore, 
and dexpramipexol, which reduces the ROS production and 
improves mitochondrial function (1). 
PROTEIN AGGREGATES
Although protein aggregates are a hallmark of neurodegener-
ation, there is still no agreement on their exact role. By bind-
ing proteins necessary for cell survival, the protein aggregates 
may lead to cell degeneration. On the other hand, they may 
protect the cell from toxic products by their direct binding. 
And finally, as by-products of pathological processes they can 
simply be markers of degeneration. There are three types of 
cellular inclusions typically found in ALS. They are hyaline 
conglomerate inclusions (HCI), Bunina bodies and ubiquina-
ted inclusions (UBI) (29). Hyaline conglomerate inclusions 
are big inclusions of phosphorylated and non-phosphorylated 
neurofilaments and random proteins or cellular organelles. 
Since they were found in a number of neurodegenerative 
diseases and control tissue, they are considered unspecific 
derivatives of various pathological processes. Bunina bodies 
are small eosinophilic inclusions found in cell bodies of mo-
tor neurons localized in the spinal cord of 80–100% SALS 
cases. They are positive for cystatin C. Similar structures 
were found in physiological aging but not in other neurode-
generative diseases. Most characteristic aggregates present 
nearly in all cases of SALS are ubiquinated inclusions. They 
were found in motor neurons of brain stem and anterior 
horns of the spinal cord. They present a variety of shapes 
from fibrillary, through skein-like to compact (‘Lewy-like’) 
inclusions. Until 2007 the main protein compound of UBI 
was unknown. They were not reactive to antibodies against 
tau protein, neurofilaments, alpha-synuclein or cystatin C, 
the elements characteristic for neurodegenerative precesses 
(30). In 2007 Mackenzie and coworkers (31) reported that 
UBI were positive for transactive response DNA-binding 
protein (TDP-43), previously described in frontotemporal 
lobe degeneration (FTLD) (32). Most interestingly, TDP-43 
was found in cases of SALS or FALS but not in FALS with 
mutation in SOD1 gene indicating a different pathological 
entity of these two conditions (33). It was further identified in 
some cases of Alzheimer’s and Parkinson disease, inclusion 
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body miositis and myopathy with rimmed vacuoles (34). In 
neurodegenerative diseases it did not however colocalize 
with tau and synuclein inclusions. Within the group of FALS, 
TDP-43 inclusions were also found in cases with ANG and 
TARDBP but not FUS/TLS mutations. TDP-43 is a 414-ami-
noacid protein encoded by TARDBP gen. In physiological 
conditions it is localized in the nucleus. However, no wt 
TDP-43 protein was found within the nuclei of the neuronal 
cells from patients affected by FTLD or ALS (35). In these 
cases all the pool of intracellular TDP-43 accumulated in the 
cytoplasm. It was subjected to hyperphosphorylation, ubiq-
uitination and cleavage to generate C-terminal fragments. 
The cytoplasmic redistribution of TDP-43 was found to be 
an early event (36). Following this discovery, mutations in 
TARDBP were found responsible for 4% of FALS and1% 
of SALS cases (33). Till now 38 disease-causing mutations 
were identified. 
RNA PROCESSING
Since TARDBP contains two RNA-recognition motifs, TDP-
43 is a RNA- and, to a lesser extent, a DNA-binding protein. It 
attaches to a TG-rich fragment of RNA within the promoter of 
HIV-1 gene to stop its transcription (37). By binding to a 3’-
UTR sequence encoding for human neurofilament light chain 
(hNFL1), it stabilizes the transcript and helps maintain the 
correct neurofilament stoichiometry (34). The plausible role 
of RNA processing in pathogenesis of ALS was reinforced 
by identification of disease causing mutations in FUS/TLS 
gene (38). It encodes for another RNA-binding protein called 
fused in sarcoma/translated in liposarcoma (FUS/TLS). FUS/
TLS is a 526-aminoacid protein encoded by 15 exons. It was 
shown to bind both RNA and DNA, and, like TDP-43, func-
tion in diverse processes including transcription, alternative 
splicing and microRNA processing (33). The mutant form 
of FUS/TLS accumulates in cytoplasm of neurons and glial 
cells although the nuclear cleavage of FUS/TLS in ALS is 
less spectacular. No ubiquitination and phosphorilation of 
the protein was ever reported. Beside ALS, FUS/TLS forms 
neuronal intranuclear inclusions in poliglutamine diseases 
such as Huntington disease and spinocerebellar ataxias (39). 
It does not however form aggregates in FALS with TARDBP 
mutations.
Thirty mutations of FUS/TLS were found in ALS, being 
responsible for 4% of FALS and rare cases of SALS. Several 
in vitro studies performed recently shaded more light on the 
role of TDP-43 and FUS/TLS in RNA processing (33). 
ALTERATIONS OF CYTOSkELETON FuNCTIONS ANd AxONAL 
TRANSPORT
Among other factors, neural cell homeostasis strongly de-
pends on axonal transport. It provides cell with neurotrophic 
factors, carries signal proteins, cell organelles, cleaved pro-
teins and membrane fragments. Human motor neurons may 
be 5000 fold larger than average cells and their axon length 
may exceed 1 meter (40). For this reason, the efficient axonal 
transport within motor neurons is particularly important. It 
depends on interactions between cytoskeleton and motor 
proteins. The cytoskeleton is composed of microtubules (MT) 
and MT-associated proteins, actin filaments/actin-associated 
proteins, and intermediate filaments, neurofilaments being 
a subtype of the latter. Microtubules are composed of as-
sembled (polymerized) tubulin heterodimers. In course of 
their formation, the tubulin dimers are preferentially added 
to the plus end of the MT assuring its growth from the cell 
body towards the periphery (41). The transport of cargoes 
by MT-dependent ATP-associated motor proteins, kinesin 
and dynein, is baseds on MT’s structural polarity. Actin fila-
ments are localized mainly in the cell cortex thus not directly 
involved in neuronal transport. Neurofilaments, run along the 
axons and their main role is to control axonal caliber. Since 
the speed of signal conduction depends on axonal diameter, 
the neurofilaments are particularly abundant in large-diameter 
axons (42). Kinesins transport synaptic vesicles, membrane 
constituents and mitochondria from the cell body towards the 
plus end of the microtubules localized in the cell periphery. 
On the contrary, neurotrophic factors, exogenous substances 
and waste membrane fragments use the retrograde transport 
mediated by the denein/dynactin complex (43). 
Several mutations of genes encoding for motor proteins have 
been found in motor neuron diseases. Hereditary spastic para-
plegia is caused by mutations of kinesin heavy chain (KIF3A) 
(44). ALS with vocal cord paralysis was linked to mutation in the 
p150 subunit of the dynactin (45) Transgenic mice harbouring 
this mutation develop progressing loss of motor neurons (46). 
Mice overexpressing dynamitin, a dynactin inhibiting protein 
also develop MND (47). Mutation of the dynein heavy chain 
produces large fibers sensory neuropathy leading to secondary 
motor neuron loss in transgenic animals (48,49). The impair-
ment of axonal transport was observed in preclinical stage of 
MND in transgenic mice with human SOD1 mutation. It was 
postulated that accumulation of SOD1 aggregates in cells with 
already impaired transport might enhance motor neuron distress 
causing cell death in the mechanism of axonal strangulation (50). 
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GLIAL CELLS INvOLvEMENT
Expression of mutated SOD1 exclusively in motor neurons 
or in glial cells does not induce MND in transgenic models 
of the disease (51). Studies with the use of transgenic chim-
ers expressing mutated human SOD1 or wtSOD1 in different 
population of cells within the same organism provided more 
evidence on the involvement of glial cells in the pathogenesis 
of ALS. It was found that expression of mutated SOD1 in some 
cells of the CNS induced the animals death in time inversely 
proportional to the number of cells harboring the mutation. 
Moreover, not all motor neurons harboring the mutation un-
derwent degeneration. When mutated SOD1 was expressed in 
all motor neurons and only in a proportion of glial cells, the 
neuronal death would depend on the number of non-neuronal 
cells harboring the mutation (52). 
The results of these studies show that the loss of motor 
neurons depends on the expression of mutated SOD1 in non-
neuronal cells and the microenvironment they create. The 
expression of mutated SOD1 in glial cells is thus indispensible 
but still insufficient to induce MND.
Another issue is the plausible toxicity of the microglia in 
MND. Microglial cells expressing mutant human SOD1 reduce 
survival of motor neurons derived from human neural stem 
cells (53). The toxicity is alleviated in the presence of stem cell-
derived astrocytes. On the other hand, IgG immune complexes 
or proinflammatory lipopolisacharides isolated from ALS 
patients are capable of inducing microglia activation, genera-
tion of ROS and release of glutamate, what induces toxicity 
towards primary motor neurons (54,55). The over-activated 
microglia is even able to render otherwise neuroprotective 
astrocytes dysfunctional and toxic to motor neurons (56). 
Anti-inflammatory treatment provides neuroprotection in the 
culture (57). The toxicity of spinal cord microenvironment 
may therefore be an important obstacle in implementation of 
stem cell-bases treatment strategies in ALS (1). 
PROGRAMMEd CELL dEATH
Although the morphological features of programmed cell 
death (apoptosis) were observed in some motor neurons of 
transgenic ALS model with SOD1 mutation, the involve-
ment of apoptosis in ALS is controversial (58,59). In hu-
mans, the post mortem studies in the spinal cord allowed 
to identify three stages of motor neurons death. In the first 
stage, called chromatolisis, there was cell edema, loss of 
Nissl substance and a translocation of the nucleus to the 
cell periphery. The second stage started with the loss of 
cell processes followed by cytoplasm homogenization and 
chromatin shrinkage. The last, apoptotic, step ended up 
with reduction of cell volume with round or fusiform shape 
formation. There was however no nucleus fragmentation 
typical for apoptotic cell death (60).
Even if the cell death in ALS does not occur in a way typical 
for classic apoptosis, several intracellular changes consistent 
with those observed in apoptosis have been found in motor 
neurons cell line NSC34, transgenic models of ALS/MND 
and ALS in humans (reviewed in 58). The up-regulation of 
caspase 9 expression was found in NSC34 cells cultured in 
the presence of mutated SOD1. Trophic deprivation resulted 
in additional activation of effector caspases 3 and 6 in the 
same model. Activation of caspase 1 and 3 was also observed 
in the spinal cord of transgenic mice in course of the disease. 
In another study, the activation of caspase 9 and 7 was ac-
companied by translocation of proapoptotic Bax protein from 
cytoplasm to mitochondria with cytochrom c release. Also in 
human post mortem studies there was an increase of caspase 
1 and 9 expression in the spinal cord as well as increased 
activity of caspase 3 in anterior horns of the spinal cord and 
motor but not sensory cortex in ALS (61). In transgenic ALS 
model with SOD1 mutation, there a decreased concentration 
of antiapoptotic Bcl-e and Bcl-xL proteins and increased ex-
pression of proapoptotic Bad and Bax proteins was observed 
in the spinal cord of symptomatic animals (59). The changes 
in human tissues are less spectacular. Immunohistochemical 
studies did not show differences between the reactivity of 
Bcl-2 and Bax proteins in ALS motor cortex and spinal cord 
compared to control. However in ALS, the proapoptotic Bax 
proteins was enriched in mitochondria compared to cytosol in 
anterior horn cells and motor cortex compared to the sensory 
cortex of the same patients (60).
CONCLuSION
Amyotrophic lateral sclerosis is a disorder of complex patho-
genesis. The role of oxidative stress and mitochondrial dys-
function is supported by the usual middle age symptom onset. 
Like in physiological aging, at this time-point the antioxidant 
mechanisms are no longer thoroughly efficient. Since a high 
percentage of oxygen is used in mitochondria, these organelles 
are also the main source of ROS. These can increase the glu-
tamate release or decrease its retrograde uptake by EAAT2. 
The NMDA-dependent influx of calcium ions induces the 
synthesis of nitric oxide (NO) within the cell, what may in 
turn lead to nitration-dependent impairment of neurofilaments 
12
Biomed Rev 22, 2011
Kuźma-Kozakiewicz
phosphorylation. The protein aggregates formed in this process 
lead to impairment of axonal transport and motor neuron death 
in the mechanism of axonal strangulation. The imbalanced 
calcium homeostasis may activate the mitochondrial pathway 
of apoptosis. The toxic environment created by the glial cells 
might further decrease the efficacy of reparatory mechanisms. 
Although the recent discovery of the involvement of DNA/
RNA binding proteins in pathogenesis of ALS shaded more 
light on the pathogenesis of ALS without SOD1 mutations, it 
did not yet allow identifying the trigger point for the motor 
neuron death in this lethal disease.
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